<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496860</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-801-01-06</org_study_id>
    <nct_id>NCT00496860</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies</brief_title>
  <official_title>Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor Bioscience Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor Bioscience Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and
      dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate
      the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic
      profile of ALT-801 in previously treated patients with progressive metastatic malignancies.
      ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting
      mechanism that recognizes tumor cells with a specific tumor marker.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most current cancer treatment strategies involve the use of chemotherapeutic or biological
      drugs that exhibit variable efficacy and considerable toxicity. The limitations are often
      the result of the adverse side effects of the therapeutic drug on normal tissues. One
      approach to control these effects is to target the therapy to the tumor site. Of the
      identified tumor antigens, the human p53 tumor suppressor protein is overexpressed in a wide
      range of human malignancies. p53 is an intracellular tumor suppressor protein that acts to
      arrest the proliferation of cells. When mutated, it loses its ability to suppress abnormal
      proliferation and exhibits a longer half-life than the wild-type protein, allowing for its
      accumulation in tumors. In addition, p53 overexpression correlates with tumor transformation
      and aggression and is associated with lower overall survival rates and resistance to
      chemotherapeutic intervention in cancer patients. Therefore, p53 appears to be a marker for
      a considerable number of human malignancies and represents a good target for
      immunotherapeutics. However, p53 cannot be used as a target for antibodies because it is not
      displayed independently on the cell surface. Instead, the p53 protein is processed
      intracellularly into peptide fragments that are then displayed on the cell surface in the
      context of major histocompatibility complex (MHC). These peptide/MHC complexes are
      recognized by T-cells via their T-cell receptors (TCRs). Recently it has been confirmed that
      the peptide fragment is significantly elevated in a wide range of human tumor tissues,
      particularly in melanoma, renal, lung, breast, colorectal, bladder, ovary, stomach,
      esophagus, lymphoma, liver, leukemia, and head &amp; neck cancer. Targeted approaches to
      concentrate therapeutic cytokines at the tumor sites that express p53 could provide
      considerable advantages over current treatment.

      Interleukin-2 (IL-2) is a well-characterized growth factor for immune effector cells which
      play critical roles in tumor control and rejection. A recombinant human IL-2 has been
      approved for treating metastatic melanoma and renal cell carcinoma. However, the major
      drawback of IL-2 therapy is its severe systemic toxicity. As a result, use of high dose IL-2
      is limited to specialized programs with experienced personnel and it is generally offered to
      patients who are responsive and have excellent organ function. Thus, there is a critical
      need for innovative strategies that enhance the effects of IL-2 or reduce its toxicity
      without compromising clinical benefits.

      The study drug, ALT-801, is a biologic compound composed of interleukin-2 (IL-2) genetically
      fused to a humanized soluble T-cell receptor directed against the p53-derived antigen. This
      study is to evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor
      sites that overexpress p53 results in clinical benefits.

      The study drug will be administered by bolus intravenous infusion in an in-patient hospital
      setting under the supervision of a qualified physician experienced in the use of anti-cancer
      agents including high dose IL-2. An intensive care facility and specialists skilled in
      cardiopulmonary or intensive care medicine must be available. There are two treatment
      cycles. For each treatment cycle, patients will be admitted to the hospital, remain in the
      hospital during the study drug infusion period, and be discharged from the hospital the day
      after the last infusion at the Principal Investigator's discretion. There is a 10-day
      resting period between the treatment cycles. Tumor assessments will be done at weeks 7 and
      11 after starting the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of serious adverse events per cohort</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum-tolerated Dose (MTD) of ALT-801</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of dose limiting toxicities (DLTs). A DLT is a toxicity that results in patient withdrawal from the study as defined in the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Antitumor Response to ALT-801</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD). CR is defined as disappearance of all tumor lesions selected for measurement. PR is defined as at least 30% decrease in the sum of all tumor lesions selected for measurement. Stable disease is defined as neither sufficient tumor shrinkage to qualify for PR nor sufficient tumor increase to qualify for progressive disease (PD) which is defined as at least 20% increase the sum of the all tumor lesions selected for measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT-801 Induced Cell-mediated Immune Responses</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of tumor-responsive (interferon-gamma positive (IFNg+)) immune cells in blood post dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of ALT-801</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Titer of anti-drug Abs at week 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Progressive Metastatic Malignancies</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-801</intervention_name>
    <description>Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ENTRY CRITERIA:

        DISEASE CHARACTERISTICS:

          -  Locally advanced or metastatic malignancies

          -  Histologically or cytologically confirmed

          -  Evaluable

          -  Surgically and medically incurable

          -  Not responding to standard therapy or no other standard therapy exists

          -  Human leukocyte antigen (HLA)-A2.1/p53 positive

        PRIOR/CONCURRENT THERAPY:

          -  No prior Proleukin therapy within one year

          -  No concurrent radiotherapy, chemotherapy, or other immunotherapy

          -  More than 4 weeks since prior major radiotherapy

          -  More than 4 weeks since prior cytotoxic therapy

          -  More than 6 weeks since prior nitrosoureas therapy

          -  More than 8 weeks since prior monoclonal antibody therapy

        PATIENT CHARACTERISTICS:

        Life expectancy

          -  &gt; 3 months

        Performance status

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

        Bone marrow reserve

          -  Absolute neutrophil count (AGC/ANC) ≥ 1,500/microliters (uL)

          -  Platelets ≥100,000/uL

          -  Hemoglobin ≥ 10g/dL

        Renal function

          -  Serum creatinine ≤ 1.5 X Upper limit of normal (ULN)

        Hepatic function

          -  Total bilirubin ≤ 1.5 X ULN

          -  Aspartate Aminotransferase (AST) ≤ 2.5 X ULN

          -  Alkaline phosphatase ≤ 2.5 X ULN

          -  Prothrombin time (PT) or international normalized ratio (INR) ≤ 1.5 X ULN

          -  Activated partial thromboplastin time (aPTT) ≤ 1.5 X ULN

        Cardiovascular

          -  May be safely tapered off anti-hypertensives if currently on anti-hypertensives

          -  New York Heart Association classification I or II

          -  No congestive heart failure &lt;6 months

          -  No unstable angina pectoris &lt;6 months

          -  No myocardial infarction &lt;6 months

          -  No history of ventricular arrhythmias

          -  Normal cardiac stress test required if any of the following is present:

               -  Over age 50

               -  History of abnormal EKG

               -  Symptoms of cardiac ischemia or arrhythmia

        Pulmonary

          -  Normal pulmonary function test (FEV1 ≥ 75% of predicted value) if any of the
             following is present:

               -  Prolonged history of cigarette smoking

               -  Symptoms of respiratory dysfunction

        Other

          -  No known autoimmune disease

          -  No known HIV positive

          -  No psychiatric illness/social situations that would limit study compliance

          -  No history or evidence of central nervous system (CNS) disease

          -  No active systemic infection requiring parental antibiotic therapy

          -  No systemic steroid therapy required

          -  No prior organ allograft

          -  Not receiving other investigational agents

          -  Not receiving chronic medication for asthma

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Cancer Pavillion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Cancer Care Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.altorbioscience.com</url>
    <description>Altor Bioscience Corporation, Miramar, Florida, US</description>
  </link>
  <link>
    <url>http://www.moffitt.org</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, Florida, US</description>
  </link>
  <link>
    <url>http://www.orlandoregional.org/mdanderson/index.aspx</url>
    <description>MD Anderson Cancer Center Orlando</description>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 17, 2013</lastchanged_date>
  <firstreceived_date>July 3, 2007</firstreceived_date>
  <firstreceived_results_date>April 2, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>p53</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>targeted</keyword>
  <keyword>metastatic</keyword>
  <keyword>malignancy</keyword>
  <keyword>malignancies</keyword>
  <keyword>interleukin-2</keyword>
  <keyword>IL-2</keyword>
  <keyword>fusion protein</keyword>
  <keyword>antitumor</keyword>
  <keyword>melanoma</keyword>
  <keyword>renal cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>kidney cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>advanced cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>breast tumors</keyword>
  <keyword>cancer of head and neck</keyword>
  <keyword>esophagus cancer</keyword>
  <keyword>lymphoma</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>ovary cancer</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>TCR</keyword>
  <keyword>T-cell receptor</keyword>
  <keyword>P53 gene</keyword>
  <keyword>p53 tumor suppressor protein</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 08-2007 and 05-2009, 118 patients were consented and screened, 56 were Human leukocyte antigen (HLA)-A2 positive and had tumor specimens that were positive for target p53 (aa 264–272)/HLA-A*0201 complex. Thirty HLA-A2–positive patients with p53/HLA-A*0201 tumors either withdrew consent or did not meet other inclusion/exclusion criteria.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ALT-801 0.015 mg/kg/Dose</title>
          <description>0.015 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="P2">
          <title>ALT-801 0.040 mg/kg/ Dose</title>
          <description>0.040 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="P3">
          <title>ALT-801 0.080 mg/kg/Dose</title>
          <description>0.080 mg/kg/dose of ALT-801</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALT-801 0.015 mg/kg/Dose</title>
          <description>0.015 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="B2">
          <title>ALT-801 0.040 mg/kg/Dose</title>
          <description>0.040 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="B3">
          <title>ALT-801 0.080 mg/kg/Dose</title>
          <description>0.080 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="65" lower_limit="50" upper_limit="79"/>
                <measurement group_id="B2" value="51" lower_limit="27" upper_limit="72"/>
                <measurement group_id="B3" value="58" lower_limit="53" upper_limit="65"/>
                <measurement group_id="B4" value="54" lower_limit="27" upper_limit="79"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="6"/>
                <measurement group_id="B4" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies</title>
        <description>Number of serious adverse events per cohort</description>
        <time_frame>18 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>ALT-801 0.015 mg/kg/Dose</title>
            <description>0.015 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O2">
            <title>ALT-801 0.040 mg/kg/Dose</title>
            <description>0.040 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O3">
            <title>ALT-801 0.080 mg/kg/Dose</title>
            <description>0.080 mg/kg/dose of ALT-801</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies</title>
            <description>Number of serious adverse events per cohort</description>
            <units>Events</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum-tolerated Dose (MTD) of ALT-801</title>
        <description>Number of dose limiting toxicities (DLTs). A DLT is a toxicity that results in patient withdrawal from the study as defined in the protocol.</description>
        <time_frame>18 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>ALT-801 0.015 mg/kg/Dose</title>
            <description>0.015 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O2">
            <title>ALT-801 0.040 mg/kg/Dose</title>
            <description>0.040 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O3">
            <title>ALT-801 0.080 mg/kg/Dose</title>
            <description>0.080 mg/kg/dose of ALT-801</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Maximum-tolerated Dose (MTD) of ALT-801</title>
            <description>Number of dose limiting toxicities (DLTs). A DLT is a toxicity that results in patient withdrawal from the study as defined in the protocol.</description>
            <units>events</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Antitumor Response to ALT-801</title>
        <description>Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD). CR is defined as disappearance of all tumor lesions selected for measurement. PR is defined as at least 30% decrease in the sum of all tumor lesions selected for measurement. Stable disease is defined as neither sufficient tumor shrinkage to qualify for PR nor sufficient tumor increase to qualify for progressive disease (PD) which is defined as at least 20% increase the sum of the all tumor lesions selected for measurement.</description>
        <time_frame>24 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>ALT-801 0.015 mg/kg/Dose</title>
            <description>0.015 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O2">
            <title>ALT-801 0.040 mg/kg/Dose</title>
            <description>0.040 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O3">
            <title>ALT-801 0.080 mg/kg/Dose</title>
            <description>0.080 mg/kg/dose of ALT-801</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Antitumor Response to ALT-801</title>
            <description>Number of subjects with a complete response (CR), partial response (PR) or stable disease (SD). CR is defined as disappearance of all tumor lesions selected for measurement. PR is defined as at least 30% decrease in the sum of all tumor lesions selected for measurement. Stable disease is defined as neither sufficient tumor shrinkage to qualify for PR nor sufficient tumor increase to qualify for progressive disease (PD) which is defined as at least 20% increase the sum of the all tumor lesions selected for measurement.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT-801 Induced Cell-mediated Immune Responses</title>
        <description>Number of tumor-responsive (interferon-gamma positive (IFNg+)) immune cells in blood post dosing</description>
        <time_frame>24 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>ALT-801 0.015 mg/kg/Dose</title>
            <description>0.015 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O2">
            <title>ALT-801 0.040 mg/kg/Dose</title>
            <description>0.040 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O3">
            <title>ALT-801 0.080 mg/kg/Dose</title>
            <description>0.080 mg/kg/dose of ALT-801</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>ALT-801 Induced Cell-mediated Immune Responses</title>
            <description>Number of tumor-responsive (interferon-gamma positive (IFNg+)) immune cells in blood post dosing</description>
            <units>IFNg spots per million PMBCs</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6433" spread="2847"/>
                  <measurement group_id="O2" value="9117" spread="1671"/>
                  <measurement group_id="O3" value="1125" spread="163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of ALT-801</title>
        <description>Titer of anti-drug Abs at week 4</description>
        <time_frame>24 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>ALT-801 0.015 mg/kg/Dose</title>
            <description>0.015 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O2">
            <title>ALT-801 0.040 mg/kg/Dose</title>
            <description>0.040 mg/kg/dose of ALT-801</description>
          </group>
          <group group_id="O3">
            <title>ALT-801 0.080 mg/kg/Dose</title>
            <description>0.080 mg/kg/dose of ALT-801</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunogenicity of ALT-801</title>
            <description>Titer of anti-drug Abs at week 4</description>
            <units>titer</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="347" spread="103"/>
                  <measurement group_id="O2" value="5483" spread="2310"/>
                  <measurement group_id="O3" value="762" spread="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ALT-801 0.015 mg/kg/Dose</title>
          <description>0.015 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="E2">
          <title>ALT-801 0.040 mg/kg/Dose</title>
          <description>0.040 mg/kg/dose of ALT-801</description>
        </group>
        <group group_id="E3">
          <title>ALT-801 0.080 mg/kg/Dose</title>
          <description>0.080 mg/kg/dose of ALT-801</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Ischemia/Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death-NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary Infiltrates</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Edema: trunk/genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmia - Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia - Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="16"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Neurology</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain - Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal - Other - Decreased urine output</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hing C. Wong, Chief Clinical Officer</name_or_title>
      <organization>Altor Bioscience</organization>
      <phone>9544438600</phone>
      <email>hingwong@altorbioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
